Evidence map›Paper›PMID 34457356›Full record

ArticleJournal of translational science2021

Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV.

H Akkiz, B I Carr, V Guerra, R Donghia, K Yalçın, U Karaoğullarından, E Altıntaş, A Özakyol, H Şimşek, H Y Balaban and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

H Akkiz *Çukurova University, Adana, Turkey.
B I Carr *İnonu University, Malatya, Turkey.
V Guerra *National Institute of Gastroenterology, S. de Bellis Research hospital, Castellana Grotte (BA), Italy.
R DonghiaNational Institute of Gastroenterology, S. de Bellis Research hospital, Castellana Grotte (BA), Italy.
K YalçınDikle University, Diyarbakır, Turkey.
U Karaoğullarındanİnonu University, Malatya, Turkey.
E AltıntaşMersin University, Mersin, Turkey.
A ÖzakyolEskişehir Osmangazi University, Eskişehir, Turkey.
H ŞimşekHacettepe University, Ankara, Turkey.
H Y BalabanHacettepe University, Ankara, Turkey.
A BalkanGaziantep University, Gazientep, Turkey.
A UyanıkoğluHarran University, Şanlıurfa, Turkey.
N EkinDikle University, Diyarbakır, Turkey.
A DelikÇukurova University, Adana, Turkey.
Cukurova University · TRDicle University · TRGastroenterology Hospital "Saverio de Bellis" · ITHacettepe University · TRInonu University · TREskişehir Osmangazi University · TRGaziantep University · TRHarran University · TRMersin Üniversitesi · TR

Funding

K VITAMINS--A NEW CLASS OF LIVER CELL GROWTH INHIBITORSR01CA082723 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CARR, BRIAN I · 2000 to 2008
$2.3M
NCI NIH HHS R01 CA082723
6 · The paper itself

Abstract

INTRODUCTION AND

aimsHepatocellular carcinoma (HCC) is a consequence of chronic liver disease, particularly from hepatitis B or C and increasingly from obesity and metabolic syndrome. Since lipids are an important component of cell membranes and are involved in cell signaling and tumor cell growth, we wished to evaluate the relationship between HCC patient plasma lipids and maximum tumor diameter and other indices of HCC human biology.

methodsWe examined prospectively-collected data from a multi-institutional collaborative Turkish HCC working group, from predominantly HBV-based patients, for plasma lipid profiles, consisting of triglycerides, total cholesterol, LDL-cholesterol (LDL) and HDL-cholesterol (HDL) and compared these with the associated patient maximum tumor diameter (MTD), portal vein thrombosis, alpha-fetoprotein (AFP) and also with patient survival.

resultsWe found that both low HDL (p=0.0002) and high LDL (p=0.003) levels were significantly associated with increased MTD, as well as in a final multiple linear regression model on MTD. The combination of low HDL combined with high HDL levels were significant in a regression model on MTD, PVT and an HCC Aggressiveness Index (Odds Ratio 12.91 compared to an Odds Ratio of 1 for the reference). Furthermore, in a Cox regression model on death, the HDL plus LDL combination had a significantly higher Hazard Ratio than the reference category.

conclusionsLow plasma HDL, high plasma LDL and especially the combination, were significantly related to more aggressive HCC phenotype and the combination was significantly related to a higher Hazard Ratio for death.

Indexed as

aggressivenessHCClipidssurvivaltumor size

Identifiers

PMID34457356
PMCPMC8389344
OpenAlexW3178121883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.